- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
NPPA fixes retail price of 7 formulations; Details
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India has fixed prices of 7 formulations.
These include some popular drug brands and combination formulations like Nebivolol and Telmisartan Tablet; Levetiracetam and Sodium Chloride Infusion; Norethisterone Acetate Tablet and so on to treat various ailments.
Prominent drugmakers like Lupin, Zydus Healthcare, Akums Drugs, and Synokem Pharma are involved in manufacturing the formulations mentioned in the list.
In exercise of the powers conferred by paragraphs 5, 11, and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 701(E) dated 10th March 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1. | Nebivolol + Telmisartan Tablet | Each uncoated bilayered tablet contains: Nebivolol hydrochloride IP eq. to Nebivolol 5 mg, Telmisartan IP 40mg | 1 Tablet | M/s Lupin Limited | 12.59 |
2. | Levetiracetam + Sodium Chloride Infusion | Each 100 ml contains: Levetiracetam IP 500mg, Sodium Chloride IP 820mg, Water for injection IP q.s. | Per 100ml Pack | M/s Akums Drugs & Pharmaceuticals Limited/M/s Lupin Limited | 91.56 |
3. | Levetiracetam + Sodium Chloride Infusion | Each 100 ml contains: Levetiracetam IP 1000mg, Sodium Chloride IP 750mg, Water for injection IP q.s. | Per 100ml Pack | M/s Akums Drugs & Pharmaceuticals Limited/M/s Lupin Limited | 148.72 |
4. | Levetiracetam + Sodium Chloride Infusion | Each 100 ml contains: Levetiracetam IP 1500mg, Sodium Chloride IP 540mg, Water for injection IP q.s. | Per 100ml Pack | M/s Akums Drugs & Pharmaceuticals Limited/M/s Lupin Limited | 206.32 |
5. | Norethisterone Acetate Tablet | Each film-coated controlled release tablet contains: Norethisterone Acetate BP 15mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd./M/s Torrent Pharmaceuticals Limited | 17.83 |
6. | Norethisterone Acetate Tablet | Each film-coated controlled release tablet contains: Norethisterone Acetate BP 10mg | 1 Tablet | M/s Zydus Healthcare Limited | 15.40 |
7. | Norethisterone Acetate Tablet | Each film-coated controlled release tablet contains: Norethisterone Acetate BP 15mg | 1 Tablet | M/s Zydus Healthcare Limited | 17.83 |
The notification further added;
(a) The manufacturer of the above-mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS, and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above
i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
For more details click on the link below:-
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751